Abstract
Over the last 10 years, accumulating evidence has confirmed the ability of dihydropyridine calcium antagonists to improve red blood cell deformability. In this review of the literature, particular attention is paid to results obtained with isradipine, a second-generation derivative of the 1,4-dihydropyridine family. Isradipine appears to be more selective in various pharmacological properties, well tolerated, easy to administer, and effective in controlling blood pressure and reducing the frequency of ischemic events. While manifesting these desirable attributes, isradipine retains an unimpaired ability to improve red blood cell deformability. It is suggested that the therapeutic efficacy of dihydropyridine calcium antagonists is attributable, at least in part, to their ability to affect blood rheology by improving red blood cell deformability.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
